Specific tetradentate copper chelating agents as anticancer agents
By developing the copper-specific tetradentate ligand TDMQ20, using it to induce ROS production and mitochondrial damage, significantly inhibiting cancer cell growth and metastasis, the problem of existing copper chelating agents lacking metal specificity and toxicity in anti-cancer treatment is solved, and the problem of existing copper chelating agents lacking metal specificity and toxicity in anti-cancer treatment is achieved. It has improved the efficient killing and safety of a variety of cancer cells.
Patent Information
- Application Number
- CN202480001464.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-12
AI Technical Summary
Existing copper chelating agents lack metal specificity and potential toxicity in anti-cancer treatment, making it difficult to effectively inhibit the growth and metastasis of cancer cells.
A series of copper-specific tetradentate ligand TDMQ series, especially TDMQ20, has been developed as a highly selective copper chelator, which significantly inhibits the growth and metastasis of cancer cells by inducing ROS production, mitochondrial damage and apoptosis.
TDMQ20 shows higher cytotoxicity and better safety for a variety of cancer cell lines, especially for non-small cell lung cancer, cervical cancer and liver cancer cells. Its effect is dose-dependent and significantly better than existing drugs. FU.
Smart Images

Figure CN118946358A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of anticancer drugs. More specifically, the present invention discloses the use of a copper chelator of a tetradentate monoquinoline (TDMQ) series as an anticancer agent. Background Art
[0002] Cancer is the second leading cause of death worldwide after cardiovascular disease. Over the years, many different cancer treatments have been developed, including surgery, radiotherapy, chemotherapy, gene therapy, and immunotherapy. Due to the complexity of cancer and the ability of cancer cells to develop drug resistance, it is absolutely necessary to develop new treatments in all these different treatment areas, including chemotherapy (V. Schirrmacher, Intern. J. Oncology, 2019, 54, 407-419; N. Vasan et al., Nature, 2019, 575, 299-309; K. Bukowski et al., Intern. J. Mol. Sci., 2020, 21, 3233).
[0003] Among the various approaches developed based on chemotherapy, the category of metal ligands has not been widely explored, although it has long been known that the content of metal ions in cancer cells may be different from that in normal cells. For example, the concentration of copper ions in metastatic cancer and malignant glioma is 1.5 times and 1.3 times that of the control group, respectively (D. Yoshida et al., J. Neuroncol., 1993, 16, 109-115). In addition, angiogenesis has been shown to be a copper-dependent process (E. Urso et al., J. Vasc. Res., 2015, 52, 172–196; L. Chen et al., Signal Transduct. Target. Ther., 2022, 7, 378). Copper is involved in tumor growth and spread (metastasis) of various cancer cells (S. Ishida et al., PNAS, 2013, 110, 19507–19512; G. Fnu et al., Front. Oncol. 2021, 11, 765329), and copper depletion has been shown to inhibit angiogenesis in various cancer cells and xenograft systems (L. Finney et al., Clin. Exp. Pharmacol. Physiol. 2009, 36, 88-94). Copper chelators such as tetrathiomolybdate, D-penicillamine or trientine have been used in assays in xenograft mice (Q. Pan et al., Cancer Res., 2002, 62, 4854-4859) and in some anticancer clinical trials, but without real success, mainly due to the lack of metal specificity of these ligands and their potential toxicity (L. Finney et al., Clin. Exp. Pharmacol. Physiol., 2009, 36, 88-94; C. Santini et al., Chem. Rev., 2014, 114, 815-862; J. Yoshii et al., Int. J. Cancer, 2001, 94, 768-773; S. Brem et al., Neurooncol. July 2005, 246-253).
[0004] Therefore, the present invention is directed to the use of highly effective and selective copper chelators as anticancer agents. Summary of the invention
[0005] The present invention initially developed a series of copper-specific tetradentate ligands named TDMQ as potential drugs for the treatment of Alzheimer's disease (AD), because it has been shown that copper homeostasis is disrupted in the brains of AD patients (see Y.Liu et al. Acc. Chem. Res., 2019, 52, 2026-2035). Then, the present invention further explored the possibility of using these ligands to reduce cancer cells from being exposed to copper ions, because these metal ions are involved in tumor growth and tumor angiogenesis (see Ishida et al. and Fnu et al., cited above). The TDMQ chelating agent series has been patented by our research group (see Y. Liu et al., China (GDUT-CNRS), May 27, 2016, No. 201610369550.X, Patent No. US10807957B2. Approved on October 20, 2020. Canada, Patent No. 3025406, approved on June 1, 2021. Japan, Patent No. 6889825, approved on May 26, 2021. Europe, Patent No. EP3466931B1).
[0006] The chemical synthesis of TDMQ ligands has been reported in the above patents and has been published (W. Zhang et al., ChemMedChem, 2018, 13, 864-704). Among all the various TDMQ ligands (see the above structure), we selected TDMQ20 as the best drug candidate because it has demonstrated suitable pharmacological characteristics in the mouse AD model (see J. Zhao et al., ACS Chem. Neurosci., 2021, 12, 140-149).
[0007]
[0008] General formula of reported TDMQ ligands.
[0009] For TDMQ20: R=5,7-dichloro-, n=m=2.
[0010] In this application, the cytotoxic and antiproliferative activities of TDMQ20 against several cancer cell lines are reported.
[0011] Furthermore, this patent discloses compounds and methods for treating cancer or inhibiting cancer metastasis.
[0012] In view of the above-mentioned medical need for more effective compounds useful in the treatment of cancer, the present invention relates to a series of highly selective copper chelators termed TDMQs which have cytotoxic activity against several cancer cell lines in vitro.
[0013] In particular, the present invention provides evidence that TDMQ20 shows varying degrees of cytotoxicity against five tested cancer cell lines. This copper chelator is particularly effective against non-small cell lung cancer A549, cervical cancer HeLa cells and liver cancer HepG2 cells at concentrations lower than that of the positive drug 5-FU. In addition, the cytotoxic effect of TDMQ20 on cancer cells is dose-dependent.
[0014] In addition, the selectivity of the chelator reported in the present invention for cancer cells and non-cancerous HaCaT cells is significantly better than that of 5-FU.
[0015] By studying the mechanism of action of TDMQ ligands on HeLa cancer cell lines, the results showed that TDMQ20 induced the production of ROS (reactive oxygen species), mitochondrial damage and apoptosis of cancer cells. TDMQ20 can also inhibit cancer cell migration.
[0016] The above results show that compared with 5-fluorouracil (5-FU), TDMQ20 has higher anti-cancer activity and better safety. 5-fluorouracil is currently used in the clinical treatment of various cancers, including breast cancer, colon cancer, rectal cancer, gastric cancer, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The effect of compound TDMQ20 on the colony-forming ability of HeLa cells after treatment for 14 days is shown. (A) Representative images of colonies formed by HeLa cells after treatment with increasing concentrations of TDMQ20 for 14 days. (B) Quantitative analysis of the clonogenic assay. **p<0.01, ***p<0.0001. "Control" represents untreated cells.
[0018] Figure 2 Cell scratch assay shows the inhibitory effect of compound TDMQ20 (at a concentration of 14.5 M) on the migration ability of HeLa cells after 24 h of treatment. (A) Representative images of scratches formed by HeLa cells after treatment with TDMQ20. (B) Quantitative analysis of scratch closure after TDMQ20 treatment. ****p < 0.0001 compared with the control group. "Control" represents untreated cells. Scale bar: 250 μm.
[0019] Figure 3Figure 2 shows the pro-apoptotic activity of TDMQ20 on HeLa cells after 48 h of incubation. (A) Quantitative analysis of necrotic cells (Q1 quadrant), early apoptotic cells (Q2 quadrant), late apoptotic cells (Q3 quadrant), and non-apoptotic cells (Q4 quadrant) using Annexin V / propidium iodide (PI) staining and flow cytometry. "Control" represents untreated cells. (B) Histogram represents the proportion of apoptotic cells in flow cytometry (Q2+Q3); "ns" indicates p>0.05, ***p<0.0001 compared with the control group.
[0020] Figure 4 ROS production induced by TDMQ20 in HeLa cells was detected by DCF fluorescence after 48 h of incubation. ***p<0.001, ***p<0.0001.
[0021] Figure 5 (A) Red / green fluorescence of HeLa cells treated with different concentrations of TDMQ20 and stained with JC-1 as an indirect measure of mitochondrial membrane potential (ΔΨm) (detected by flow cytometry). (B) Histogram showing the data of panel A as the mean of three independent experiments; ± SD ****p < 0.0001 compared with the control group. DETAILED DESCRIPTION
[0022] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0023] Unless otherwise specified, the experimental methods used in the examples of the present invention are all conventional methods; the materials, reagents, etc. used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0024] TDMQ refers to a series of compounds of formula (I).
[0025] The term "tetradentate monoquinoline copper chelator" refers to TDMQ. Based on previous studies, TDMQ as a "copper chelator" can be used to treat Alzheimer's disease.
[0026] 5-FU stands for 5-fluorouracil, which is currently used clinically as an anticancer agent.
[0027] Cancer mainly refers to various malignant tumors. Tumors include but are not limited to malignant melanoma, lung cancer, breast cancer, cervical cancer, colon cancer, melanoma, squamous cell carcinoma of the skin, liver cancer, osteosarcoma, prostate cancer and uveal melanoma.
[0028] The structural formula of compound TDMQ20 is as follows:
[0029]
[0030] Example 1: Pharmacological activity of TDMQ ligands against different cancer cell lines
[0031] Cytotoxic to cancer cells, selective for non-cancerous cells
[0032] The cytotoxicity of several compounds from the TDMQ series, especially TDMQ20, was evaluated on several human cancer cell lines and compared with the clinically used anticancer drug 5-fluorouracil (5-FU) as a control.
[0033] The targeted human cancer lines are 1) metastatic melanoma A375, 2) non-small cell lung adenocarcinoma A549, 3) melanoma COLO-829, 4) cervical cancer HeLa, 5) hepatocellular carcinoma HepG2. The human immortalized keratinocyte cell line HaCaT is used as a non-cancerous reference cell line.
[0034] MTT assay for cell viability: In this test, applied colorless thiazolyl blue is reduced by mitochondrial succinate dehydrogenase to produce a purple formazan that is quantified by UV-visible spectroscopy at 570 nm.
[0035] Cell viability depended on the concentration of TDMC20, and the anticancer activity of TDMC20 was quantified as the inhibition of each cell line (IC 50 ) drug concentration at which growth was 50%.
[0036] The pharmacological results are shown in Table 1.
[0037] Table 1 Survival rates of several cell lines treated with TDMQ20 for 48 h as determined by MTT assay Results are the mean ± SD (μM) of at least three independent experiments
[0038]
[0039]
[0040] TDMQ20 showed higher cytotoxicity (lower IC 50 Its cytotoxicity to non-small cell lung cancer A549, cervical cancer HeLa cells and liver cancer HepG2 cells is particularly high, and its IC 50 The values were in the range of 14-16 μM, and the IC 50 The value was lower than that of the reference drug 5-FU. The cytotoxicity (IC 50=41 μM) is lower than the cytotoxicity of the reference drug 5-FU. The selectivity (SI) of TDMQ20 for A549 cells, HeLa cells and HepG2 cell lines relative to non-cancerous cell HaCaT [SI = IC 50 (HaCaT) / IC 50 (cancer cells)] is in the range of 2.5 to 2.8. Its safety is better than that of 5-FU.
[0041] These results indicate that TDMQ20 is dose-dependently cytotoxic against several human cancer cell lines. The cytotoxicity is higher than that of the reference drug 5-FU (four-fold higher against lung adenocarcinoma A549 cells). TDMQ20 is selective for cytotoxicity against cancer cells relative to non-cancerous HaCaT cells (SI ≥ 2.5).
[0042] Antiproliferative activity of TDMQ20 on HeLa cells
[0043] Cell clone formation assay: HeLa cells were exposed to various concentrations of TDMQ20, and the proliferation of HeLa cells was evaluated on day 14. The number of HeLa cells treated with TDMQ20 decreased dramatically as the drug concentration increased from 1.5 to 12 μM. At a concentration of TDMQ20 = 12 μM, no HeLa cells could be detected.
[0044] The colony-forming ability of HeLa cells treated with TDMQ20 Figure 1 shown.
[0045] Cell scratch assay: The migration ability of HeLa cells in the presence of TDMQ20 was evaluated using a wound healing assay monitored by optical microscopy. Measurement of the width of the scratch formed in the cell monolayer after 24 hours of drug treatment quantified the migration rate of the cells. This method simulates cell migration during the in vivo scratch healing process. For cancer cells, cell migration is involved in several processes such as tumor invasion, angiogenesis, and metastasis (X. Wang et al., BMC Pharmacol. Toxicol. 2019, 20, 4).
[0046] In vitro, 14.5 μM TDMQ20 significantly inhibited HeLa cell migration to close scratches created in the cell monolayer, indicating that the drug exhibited an anti-cell migration effect.
[0047] The antiproliferative activity of TDMQ20 in cell clone formation assay and “scratch assay” indicated that TDMQ20 should be able to inhibit tumor growth and metastasis.
[0048] Example 2: Inhibitory mechanism of TDMQ ligand on HeLa cancer cell line
[0049] TDMQ20 promotes cell apoptosis
[0050] The pro-apoptotic activity of TDMQ20 in HeLa cells was evaluated using the annexin V-FITC / PI method (FITC and PI stand for 5-fluorescein isothiocyanate and propidium iodide, respectively) after 48 h of incubation with the drug. After staining, live cells showed little or no fluorescence (annexin V- / PI-), early apoptotic cells showed green fluorescence (annexin V+ / PI-), and late apoptotic cells and necrotic cells showed red and green fluorescence (annexin V+ / PI+). Cells were detected by flow cytometry. IDEAS software was used for data acquisition, and FlowJo vX software was used for data analysis. The results are shown in Figure 2. Figure 3 When HeLa cells were treated with TDMQ20 at concentrations of 14.5 μM, 7.3 μM, and 3.7 μM, the total proportion of apoptotic cells, including early apoptosis (quadrant Q2), late apoptosis (quadrant Q3), or necrosis (quadrant Q1), was 51%, 15%, and 9%, respectively. Therefore, TDMQ20 induced apoptosis in HeLa cells in a dose-dependent manner.
[0051] TDMQ20 induces excessive production of reactive oxygen species (ROS)
[0052] Cells continuously produce reactive oxygen species during aerobic metabolism. The production of ROS plays an important protective and functional role in the immune system. Cells are equipped with a powerful antioxidant defense system to combat the excessive production of ROS. Oxidative damage is thought to play an important role in many human diseases, including cancer, and occurs when the production of ROS exceeds the cells' natural antioxidant defenses.
[0053] The most direct technique for measuring the production of reactive oxygen species in cells is to use the cell-permeable fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA). In the presence of ROS (mainly H2O2), H2DCF is rapidly oxidized to 2,7-dichlorodihydrofluorescein (DCF), which has high fluorescence, with excitation and emission wavelengths of 498 and 522 nm, respectively. The stained cells were analyzed by flow cytometry and analyzed by FlowJo vX software (E.Eruslanov et al., Methods Mol.Biol.2010,594,57-52).
[0054] The results are as follows Figure 4As shown in Figure 3, the fluorescence of DCF in HeLa cells incubated with TDMQ20 at 3.7 μM, 7.3 μM, and 14.5 μM was 125%, 138%, and 150% of that in control cells, respectively, after 48 h of incubation with the drug. Thus, TDMQ20 induced a dose-dependent increase in ROS production in treated HeLa cells.
[0055] TDMQ20 induces collapse of mitochondrial inner membrane potential (ΔΨm)
[0056] The direction of the mitochondrial membrane potential (electronegativity inside the organelle) allows the inward transport of cations and the outward transport of anions, thereby promoting the accumulation of cations in mitochondria. This electrochemical gradient drives the synthesis of ATP. However, during apoptosis, the mitochondrial membrane potential (ΔΨm) decreases because this process is related to the opening of the mitochondrial permeability pore and the loss of the electrochemical gradient. Therefore, ΔΨm is a basic parameter of mitochondrial function and can be used as an indicator of cell health because mitochondria are involved in the apoptotic process of cells (DR Green et al., Science 1998, 281, 1309-1312).
[0057] The fluorescent permeabilizer JC-1 dye exhibits potential-dependent accumulation in mitochondria, forming JC-1 aggregates, and diffuses in mitochondria to form a monomeric state upon depolarization. JC-1 monomers and JC-1 aggregates show green fluorescence (peak emission at 527nm) due to healthy (non-apoptotic) cells and apoptotic cells, respectively. JC-1 aggregates also exhibit red fluorescence (peak emission at 590nm), which is a characteristic of apoptotic cells. The higher the ΔΨm, the higher the red shift of the dye (the more aggregates formed); vice versa, the lower the ΔΨm of the mitochondria, the lower the red-green ratio of the fluorescent label (few aggregates are formed). Therefore, the ratio of red / green fluorescence intensity is of great significance to the integrity and function of mitochondria, and mitochondrial depolarization is indicated by a decrease in the ratio of red to green fluorescence intensity. (LDZorova et al., Anal. Biochem. 2018, 552, 50-59; F. Sivandzade et al., Bio-Protocol. 2019, 9, e3128).
[0058] This method was used to assess mitochondrial membrane potential in HeLa cells incubated with different concentrations of TDMQ20 for 48 h, stained with JC-1, and quantified by flow cytometry processed with FlowJov.X software.
[0059] The results are as follows Figure 5 As shown in Figure 2, when the concentration of TDMQ20 increases, the red / green fluorescence ratio decreases sharply ( Figure 5B) shows that the mitochondrial membrane potential collapsed, indicating that drastic changes have occurred in the mitochondria.
[0060] Results and Discussion
[0061] TDMQ20 showed varying degrees of cytotoxicity against the five cancer cell lines tested. It was particularly effective against non-small cell lung cancer A549, cervical cancer HeLa cells, and liver cancer HepG2 cells. 50 The values were in the range of 14-16 μM, significantly lower than the reference drug 5-FU, and this effect was dose-dependent. In addition, the selectivity of TDMQ20 for non-cancerous HaCaT cells and cancer cells was significantly higher than that of 5-FU.
[0062] Further studies have shown that TDMQ20 inhibits HeLa cell migration in vitro, cell clone formation assay and cell scratch assay at 3-15 μM, indicating that the drug has the ability to inhibit cancer cell proliferation and metastasis in vivo. This effect of TDMQ20 is dose-dependent in vitro.
[0063] Preliminary studies on the mechanism of action of TDMQ20 on HeLa cells in vitro showed that TDMQ20 (i) enhanced the production of ROS, (ii) significantly reduced the mitochondrial membrane potential ΔΨm, and (iii) induced apoptosis. In fact, the occurrence of these three phenomena is expected because they are linked. Mitochondrial outer membrane permeabilization and the release of cytochrome c promote the activation of caspases in cells and the execution of apoptosis. The first target of activated caspases is the permeabilized mitochondria themselves, resulting in interrupted electron transport, loss of ΔΨm, decreased ATP levels, ROS production (due to electron disorientation in the respiratory chain), and loss of mitochondrial structural integrity. Therefore, the reduction of ΔΨm is a key event in the process of apoptosis (Q. Chen et al., Blood 1998, 92, 4545-4553; J.-E. Ricci et al., Cell 2004, 117, 773-786).
[0064] The data obtained strongly support the selection of TDMQ20 as a drug candidate for several human cancers.
[0065] Obviously, the specific implementation scheme described above is only a further detailed description of the purpose, technical scheme and beneficial effects of the present invention. It should be understood that the above is only a specific example of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for treating cancer and preventing cancer metastasis, characterized in that: comprising administering an effective amount of a compound of formula (I); wherein Y represents a group having the formula: (CH2) n –NH–(CH2) m -N(CH3)2, n and m represent 1, 2 or 3, R5, R6 and R7 are the same or different and independently represent a hydrogen atom, a chlorine atom, a fluorine atom or a trifluoromethyl group.
2. The content of claim 1, characterized in that: TDMQ20 described by formula (1) wherein n=m=2, R5=R7=Cl, R6=H is a preferred molecule for the manufacture of a drug for treating cancer; the drug includes an acceptable series of TDMQ salts; the hydrochloride form is the preferred form.
3. The content according to claim 1 or 2, characterized in that: The compounds inhibit cancer cell proliferation or migration.
4. The content according to claim 3, characterized in that: It prevents cancer cell proliferation or migration by inducing ROS production, mitochondrial damage and apoptosis.
5. The content according to claim 3, characterized in that: Wherein the cancer cell is in a mammal.
6. The content according to claim 5, characterized in that: Wherein the mammal is a human.
7. The method according to claim 1 or 2, characterized in that: Among the compounds of formula (I) useful as pharmaceuticals are acceptable salts of the TDMQ series; the hydrochloride form of the compound is the preferred form.
8. The content according to claim 1, characterized in that: Cancer refers to malignant tumors; malignant tumors include but are not limited to the following tumors: malignant melanoma, lung cancer, breast cancer, cervical cancer, colon cancer, melanoma, squamous cell carcinoma of the skin, liver cancer, osteosarcoma, prostate cancer and uveal melanoma.
9. The method according to claim 6, characterized in that This includes treating or preventing lung cancer, liver cancer, or malignant melanoma.
10. The method according to claim 6, characterized in that Among them, TDMQ20 has strong cytotoxicity against several human cancer lines in vitro, especially against non-small cell lung cancer A549, cancer HeLa cells and liver cancer HepG2.
Citation Information
Patent Citations
8-hydroxyquinoline compound, preparation method thereof and application of 8-hydroxyquinoline compound in preparation of antitumor drugs
CN116410132A
